Economic Disclosures

How BRILL.health is funded, in plain terms.

Who pays for the platform

BRILL.health earns revenue from two sources: sponsoring partners of specific programs, and individual patients who purchase a-la-carte services directly. Patients who enroll in a sponsored program pay nothing for that program — the program sponsor covers the infrastructure and processing fees.

Sponsored programs

When a program is offered in partnership with a sponsor (for example, a lab offering a screening panel at no cost to you), the sponsor pays BRILL.health a processing fee for each patient who enrolls. This fee compensates us for:

  • Identity verification to healthcare-grade standards
  • Program-specific consent capture and audit trail
  • Questionnaire delivery and structured data return to the sponsor
  • Ongoing patient-held record of the program enrollment

We do not receive payment tied to your test results, the care pathway you choose afterward, or whether you accept or decline any follow-up recommendation. Our processing fee is the same regardless of your downstream decisions.

What this means for you

  • You pay nothing for sponsored programs. The sponsor does.
  • Our economic incentive is to deliver the program accurately and reliably — not to influence your clinical decisions.
  • You are free to decline enrollment at any point in the onboarding flow, and you remain free to revoke program consent after enrollment under the terms described in our Privacy Policy.

Current sponsored program

Hereditary Cancer Screening — offered in partnership with Phi Life Sciences. Processing fee structure is being finalized; specific terms available to qualified reviewers on request.

Non-sponsored services

For services you purchase directly (for example, Remote Online Notarization of healthcare directives), the fee is paid by you, clearly disclosed at the point of service, and no sponsor is involved.

Informed by the principles of financial transparency laid out in ASCO's 2014 Policy Statement on genetic and genomic testing for cancer susceptibility (Lu KH et al., J Clin Oncol 32:833). Draft language; counsel review in progress. Last updated .